After Johnson & Johnson ended its bid, France's Sanofi is reported to be the next suitor in waiting for a tie-up with Europe's largest biotechnology drug maker, Actelion. As Ciara Lee reports, a deal could value Actelion at as much as $30 billion.
Read more
No comments:
Post a Comment